Early adaptive immune suppression in children with septic shock: a prospective observational study

Table 1 Patient demographics

Characteristic	All	Persistent or nosocomial infection,	No persistent or nosocomial infection	P ^a
	(n = 22)	(n = 6)	(n = 16)
Age, years	1.3 [0.3–14]	8 [0.9 – 16]	0.9 [0.2–12]	0.1
Female gender, n (%)	10 (45)	2 (33)	8 (50)	0.6
Complex chronic condition, n (%)	8 (36)	3 (50)	5 (31)	1
Initial OFI ≥ 3, n (%)^b	10 (45)	5 (83)	5 (31)	0.06
Initial PRISM III^b	11.5 [9 – 14]	10.5 [8.8 – 12.5]	13 [8 – 16]	0.4
Initial PELOD^b	12 [11 – 18]	12 [1 – 14]	12 [11 – 21]	0.3
Site of initial infection, n (%)
Culture negative	4 (18)	0	4 (25)
Blood	4 (18)	2 (33)	2 (13)
Lung	8 (36)	3 (50)	5 (31)
Urine	2 (9)	0	2 (13)
Abdomen	1 (5)	0	1 (6)
Multisite	3 (14)	1 (17)	2 (13)
Glucocorticoid use, n (%)^c
MP/Dex for < 24 hours^d	8 (36)	1 (17)	7 (44)	0.4
MP/Dex for > 24 hours	4 (18)	3 (50)	1 (6)	0.046
HCTZ for > 24 hours^d	4 (18)	0	4 (25)	0.5
Outcomes
ICU-free days in 28 days	17 [10 – 21]	5.5 [0–16]	19.2 [15 – 22]	0.05
Mortality, n (%)	2 (9)	1 (17)	1 (6)	0.4

^aPersistent or nosocomial infection versus no persistent or nosocomial infection (Mann–Whitney or Fisher Exact test). ^bValues at the time of sepsis onset. ^cGlucocorticoid use within 7 days of sepsis onset. ^dIncludes two patients treated with HCTZ and with MP/Dex for less than 24 hours. PRISM, Pediatric Risk of Mortality; PELOD, Pediatric Logistic Organ Dysfunction; OFI, Organ Failure Index; MP, methylprednisolone; Dex, dexamethasone; HCTZ, hydrocortisone. Data are median (IQR), except where otherwise specified.

ISSN: 1364-8535